In Section A, contributors will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Further contributors might be enrolled in the determined monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment C, https://abbv-744-brd4-inhibitor-m91346.ziblogs.com/32096173/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know